
|Articles|December 2, 2020
- December digital edition 2020
- Volume 12
- Issue 12
Quiz answers: Know the ocular effects of eyelash growth serums
Author(s)Brooke Henson, Editor
Advertisement
1. Which of the following ingredients is recognizable as a synthetic prostaglandin analog in over the counter eye-lash growth serum (OTC-ELGS)?
a. Copper tripeptide-10
b. Isopropyl cloprostenate
c. Myristoyl octapeptide-1
d. Timolol
2. Which country mentioned in the article has banned the use of synthetic prostaglandins in OTC-ELGS?
a. United States
b. Sweden
c. United Kingdom
d. Canada
3. The ideal eyelash length for optimal eye-health is:
a. One-third horizontal iris diameter
b. One-third interpupillary distance
c. One-third eye width, canthus to canthus
d. One-third eye fissure opening vertically
4. Bimatoprost use results in longer, thicker eyelashes with more melanin deposition due to the pharmaceutical’s effect on which growth phase of the eyelash?
a. Anagen
b. Tetragen
c. Catagen
d. Telogen
5. Which of the following is NOT a potential side effect of prostaglandin analogs?
a. Eyelid skin hyperpigmentation
b. Increased intraocular pressure
c. Eye pruritis (itching)
d. Conjunctival hyperemia
Articles in this issue
almost 6 years ago
New ways to keep dry eye patients comfortable in contact lensesalmost 6 years ago
ODs look back on 2020almost 6 years ago
Cataract surgery 2020 updatealmost 6 years ago
Long-term follow-up of angiod streaksalmost 6 years ago
Can AI rescue physicians from EHR woes?almost 6 years ago
How to handle dry eye follow-up visitsalmost 6 years ago
Quiz: Know the ocular effects of eyelash growth serumsalmost 6 years ago
Know the ocular effects of eyelash growth serumsalmost 6 years ago
How to manage orbital fracturesalmost 6 years ago
Navigate postop IOP control with wound burpingAdvertisement
Related to this article

Host Hamza Shah, OD, MS, FAAO, is joined by Cory Lappin, OD, MS, FAAO, to discuss dynamic muscle stimulation for dry eye, spurred by a paper on improving blinking in dry eye patients.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Takeaways from this week in optometry: October 16-23
2
BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
3
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
4
More than monitoring: Using AMD visits to promote healthy vision aging
5
